According to a recent study published in The LANCET Oncology, which treatment option is considered and should remain the standard of care for soft-tissue sarcoma?
D. Gemcitabine plus doxorubicin
Researchers found that after a median follow-up of 22 months, the proportion of patients alive and progression-free at 24 weeks did not differ significantly between those receiving doxorubicin and those receiving gemcitabine plus doxorubicin (23.3 weeks vs 23.7 weeks, respectively). Therefore, they concluded that doxorubicin should remain the standard of care in the first-line setting for most patients with advanced soft-tissue sarcoma. To read the full study, click here.